

ASX Release

SUDA Enters into Collaborative Research Agreement with Imperial College London and Appoints Professor Karadimitris as Chairman of its Scientific Advisory Board

PERTH, AUSTRALIA – 16 August 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, has entered into a Collaborative Research Agreement (CRA) with Imperial College London. In addition, the Company is pleased to announce that Professor Anastasios Karadimitris, has been appointed, through Imperial Consultants, as Chairman of its Scientific Advisory Board (SAB) for the iNKT cell therapy program.

On 18 June 2021, SUDA announced that it has entered into a Licence Agreement for the invariant Natural Killer T (iNKT) cell therapy platform developed in the laboratory of Professor Karadimitris at Imperial College London. In preclinical studies, the iNKT cell therapy platform outperformed conventional cell therapies at initial clearance of tumour cells and promoting long-term mouse survival. Another major feature of the iNKT cell therapy platform is that it will be developed to be used off-the-shelf, as iNKT cells do not cause common side effects that confine other cell therapies to using a patient’s own cells for their cancer treatment.

Under the CRA, SUDA will fund ongoing research in the laboratory of Professor Karadimitris, which will focus on creating additional intellectual property for the technology. The initial focus of the platform is for the treatment of blood cancers and the research will enable SUDA to optimise the therapy and to expand into additional cancers of unmet need, creating additional intellectual property for the platform. The research agreement is for a period of two years and is extendable by mutual agreement from each party.

SUDA’s CEO and Managing Director, Dr Michael Baker, commented, “We are excited to solidify the partnership with Imperial College London through a research collaboration – and that Professor Karadimitris is joining us, on an independent basis, as the Chair of the SAB. We look forward to continuing the research in the laboratory of Professor Karadimitris and to broadening the platform by creating new intellectual property.”

For and on behalf of the Board and for further information, please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a biotechnology company focused on developing therapies to treat human disease. SUDA's two focus areas are oncology and conditions that impact the central nervous system. SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit www.sudapharma.com

About Imperial College London

Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business.

Imperial is the world's fifth most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.

Imperial staff, students and alumni are working round-the-clock to combat COVID-19. Imperial has nearly two thousand key workers, and is at the forefront of coronavirus epidemiology, virology, vaccine development and diagnostics. More than one thousand Imperial staff and students are volunteering to support the NHS.

Imperial Consultants is the wholly owned consultancy company of Imperial College London. It provides access to the academic expertise and state of the art facilities at Imperial, on an independent basis, to deliver innovative solutions to meet the needs of industry, government and the third sector, globally.

www.imperial.ac.uk

This announcement contains certain statements which may constitute forward-looking statements or information (“forward-looking statements”), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company’s directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.